216 related articles for article (PubMed ID: 37143440)
21. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
[TBL] [Abstract][Full Text] [Related]
22. GISTs with
Cao Z; Li J; Sun L; Xu Z; Ke Y; Shao B; Guo Y; Sun Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612101
[TBL] [Abstract][Full Text] [Related]
23. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
[TBL] [Abstract][Full Text] [Related]
24. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
Solomon JP; Linkov I; Rosado A; Mullaney K; Rosen EY; Frosina D; Jungbluth AA; Zehir A; Benayed R; Drilon A; Hyman DM; Ladanyi M; Sireci AN; Hechtman JF
Mod Pathol; 2020 Jan; 33(1):38-46. PubMed ID: 31375766
[TBL] [Abstract][Full Text] [Related]
25.
Overbeck TR; Reiffert A; Schmitz K; Rittmeyer A; Körber W; Hugo S; Schnalke J; Lukat L; Hugo T; Hinterthaner M; Reuter-Jessen K; Schildhaus HU
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296928
[TBL] [Abstract][Full Text] [Related]
26. NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine.
Zito Marino F; Pagliuca F; Ronchi A; Cozzolino I; Montella M; Berretta M; Errico ME; Donofrio V; Bianco R; Franco R
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466202
[TBL] [Abstract][Full Text] [Related]
27. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
[TBL] [Abstract][Full Text] [Related]
28. The oncogenic roles of NTRK fusions and methods of molecular diagnosis.
Aref-Eshghi E; Lin F; Li MM; Zhong Y
Cancer Genet; 2021 Nov; 258-259():110-119. PubMed ID: 34710798
[TBL] [Abstract][Full Text] [Related]
29. Feasibility of two-step approach for screening NTRK fusion in two major subtypes of non-small cell lung cancer within a large cohort.
Dong K; Zhu Y; Liu X; Sun W; Yang X; Chi K; Jia L; Diao X; Huang X; Zhou L; Lin D
Hum Pathol; 2024 Jun; 149():39-47. PubMed ID: 38866255
[TBL] [Abstract][Full Text] [Related]
30. TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by
Cappellesso R; Nicolè L; Del Fiore P; Barzon L; Sinigaglia A; Riccetti S; Franco R; Zito Marino F; Munari G; Zamuner C; Cavallin F; Sbaraglia M; Galuppini F; Bassetto F; Alaibac M; Chiarion-Sileni V; Piccin L; Benna C; Fassan M; Mocellin S; Dei Tos AP
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499693
[TBL] [Abstract][Full Text] [Related]
31. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
Vingiani A; Lorenzini D; Conca E; Volpi CC; Trupia DV; Gloghini A; Perrone F; Tamborini E; Dagrada GP; Agnelli L; Capone I; Busico A; Pruneri G
Cancer Biomark; 2023; 38(3):301-309. PubMed ID: 37545217
[TBL] [Abstract][Full Text] [Related]
32. Detection of
Solomon JP; Hechtman JF
Cancer Res; 2019 Jul; 79(13):3163-3168. PubMed ID: 31196931
[TBL] [Abstract][Full Text] [Related]
33. Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer.
Conde E; Hernandez S; Sanchez E; Regojo RM; Camacho C; Alonso M; Martinez R; Lopez-Rios F
Arch Pathol Lab Med; 2021 Aug; 145(8):1031-1040. PubMed ID: 33112951
[TBL] [Abstract][Full Text] [Related]
34. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
[TBL] [Abstract][Full Text] [Related]
35. Molecular and Cytogenetic Features of NTRK Fusions Enriched in BRAF and RET Double-Negative Papillary Thyroid Cancer.
Wu S; Liu Y; Li K; Liang Z; Zeng X
J Mol Diagn; 2023 Aug; 25(8):569-582. PubMed ID: 37236546
[TBL] [Abstract][Full Text] [Related]
36. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.
Kong Y; Bu R; Parvathareddy SK; Siraj AK; Siraj N; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Eur J Endocrinol; 2021 Apr; 184(4):503-511. PubMed ID: 33524004
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
38. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach.
Hernandez S; Conde E; Molero A; Suarez-Gauthier A; Martinez R; Alonso M; Plaza C; Camacho C; Chantada D; Juaneda-Magdalena L; Garcia-Toro E; Saiz-Lopez P; Rojo F; Abad M; Boni V; Del Carmen S; Regojo RM; Sanchez-Frias ME; Teixido C; Paz-Ares L; Lopez-Rios F
Arch Pathol Lab Med; 2024 Mar; 148(3):318-326. PubMed ID: 37270803
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of cancers with NTRK gene fusions.
Gatalica Z; Xiu J; Swensen J; Vranic S
Mod Pathol; 2019 Jan; 32(1):147-153. PubMed ID: 30171197
[TBL] [Abstract][Full Text] [Related]
40. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.
Haberecker M; Töpfer A; Melega F; Moch H; Pauli C
Histopathology; 2023 Jun; 82(7):1003-1012. PubMed ID: 36759438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
